简短通讯：新诊断的HIV感染者中携带拉米夫定耐药突变的乙型肝炎病毒传播

Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.

作者信息

Treviño Ana, Soriano Vincent, Madejon Antonio, Rodriguez Carmen, Barros Carlos, Botecchia Marcelle, Tuma Paula, Del Romero Jorge, de Mendoza Carmen

机构信息

Service of Infectious Diseases, Hospital Carlos III, Hospital de Mostoles, Madrid, Spain.

出版信息

AIDS Res Hum Retroviruses. 2009 Dec;25(12):1273-6. doi: 10.1089/aid.2009.0119.

DOI:10.1089/aid.2009.0119

PMID:20001517

Abstract

From 1519 newly diagnosed HIV individuals seen in Madrid between the years 2000 and 2008, 65 (4.3%) were HBsAg(+). Two HIV/HBV-coinfected patients showed the lamivudine resistance mutation M204V in HBV while no drug resistance mutations were recognized in HIV. None of them admitted prior exposure to antiretroviral drugs. Thus, HIV/HBV-coinfected patients might benefit from baseline drug resistance testing for both HIV and HBV to optimize the selection of anti-HBV active antiviral therapy.

摘要

在2000年至2008年期间于马德里就诊的1519例新诊断的HIV感染者中，65例（4.3%）为HBsAg阳性。2例HIV/HBV合并感染患者的HBV出现了拉米夫定耐药突变M204V，而HIV未发现耐药突变。他们均未承认既往有抗逆转录病毒药物暴露史。因此，HIV/HBV合并感染患者可能会从HIV和HBV的基线耐药检测中获益，以优化抗HBV活性抗病毒治疗的选择。